¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º -{h   
J H.K.C(  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ >k']T/%  
^s\3/z>b4!  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) A5#y?Aq  
XwM611  
1. ICAM-1 4([.xT  
8GJdRL(  
2. interleukin 12(IL-12) /EwGW  
"Clz'J]{  
3. tumor infiltrating lymphocyte Dj-s5pAW  
Np)3+!^1"  
4. TCR/CD3 complex jdeva t,&u  
$#o1MX  
5. hematopoietin receptor family vUQFQ  
3l!NG=R  
6. individual idiotype(IdI) T+"f]v  
zIQzmvf  
7. integrin 9T2xU3UyY  
" oy\_1|  
8. colony-stimulatory factor (CSF) &UAe!{E 0  
uMXc0fs!$  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© +2cs#i  
f F?6j   
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? w=r&?{  
L3y5a?G  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ty1fcdFZM  
T!q_/[i~7  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ SVP:D3)  
)&NAs  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ (4~WWU (iT  
,-*iCs<  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) f~& a-  
dK?); *w]  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ _pDjg%A>n  
K\=8eg93Z  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) oC dGQ7G}  
=v2%Vs\7k  
3. immunoglobulin superfamily (IgSF) ]Bu DaxWN  
UKB_Yy^Y  
4. selectin \d68-JS@~  
MZm'npRf  
5. anti-idiotypic antibody (¦ÁId) VK .^v<Yo  
Cyk s  
6. major histocompatibility complex(MHC) bAhZ7;T~  
n E :'Zxj  
7. immunotolerance tjzA)/T,4  
K^ D82tP  
8. biological reponse modifier(BRM) R$0U<(/  
[!+D <Y  
9. immune reponse gene (Ir gene) d.}}s$Q  
iz x[  
10. reshaped antibody (or reconstituted antibody) wa?+qiWnrl  
E2:D(7(;l  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© <c%n?QK{  
v5Y@O|i#  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ c IZc:   
K`+vfqX  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? p$OD*f_b  
;/A}}B]y  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ O)<r>vqe}  
pI^=B-7  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? &q>h *w 4O  
'5WN,Vy8.  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ wO.B~`y  
@^HwrwRA  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? fk\5D[j^  
c% yh(g  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ BD4"pcr  
p2a?9R  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 0# UAjT3  
(\uA AW"  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? x 8M#t(hw  
z (#Xca  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ B%(K0`G#X  
|$w0+bV*  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: r&/D~g\"|[  
+DxifXtB  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: }{#7Z8   
*  S{\#s  
ÃâÒßѧ KMe.i'  
{V=vn L--  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© B~4mk  
2}|vWKej{  
1. CD8 K.r!?cfv  
>]C<j4  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) h bdEw=r?  
@u<0_r t  
3. immunoglobulin fold(Ig fold) .0KOnLdK  
@ikUM+A {  
4. cadherin (Ca-dependent cell adhesion moleculers) {MA@ A5  
@b8X%0B7  
5. idiotype-anti-idiotypic antibody immune network theory ^ Y# @$c  
|#!eMJ&0  
6. HLA class II antigen US"2O!u  
J~fuW?a]r  
7. complementarity-determining region (CDR) 4h(jw   
7d%A1}Bq$  
8. perforin(or pore-forming protein ,PFP) z`;&bg\8  
tc!!W9{69  
9. high affinity IL-2 receptor vRq=m8  
fc["  
10. artificial active immunization ZKZl>dDuh  
^7J~W'hI  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© c&0;wgieg  
q+r ` e  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ|;X?">7NW  
ab8oMi`z  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 >Iu]T{QNO  
TW'E99wG  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ ]Y?{$M G  
uEc0/ a :.  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ h[Ndtq>3{  
C.b,]7i  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ } IIK~d,  
m~Kch~~]  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? @&!=m]D*  
94Kuy@0:+  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ M63s(f  
*u:;:W&5y  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ aYv'H   
L:|X/c9r[  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ]Ct`4pA  
c,3'wnui  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ xI. Orpw  
9 AQ96  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© N'lGA;}i  
doxdRYKL  
1. immunoglobulin gene rearrangement 1B9Fb.i  
e]dPF[?7  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) m11"i=S"  
"/ a*[_sV  
3. flow cytometry(FCM) Z>>gXh<e[  
FOlA* U4U  
4. carrier effect Zh@4_Z9n!  
6ywnyh  
5. positive selection of T lymphocytes in thymus pAUfG^v  
a`[?,W:q  
6. mouse TH1(Th1) and TH2(Th2) subsets 6,V.j>z  
m-Z'K_oQ  
7. perforin (pore-forming protein ,PFP) U 3wsWSO  
yPzULO4  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) FJn~ =hA  
]sm0E@1  
9. SH-2(src-homology region 2) U l7pxzj  
w>9H"Q[  
10. Ab2¦Â (internal image) @2%VU#!m  
mhJOR'2  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© kw}ISXz v  
~' Qpf 8)  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? [# tT o;q  
NBbY## w0  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? S7#^u`'Q_^  
hNR >Hy\  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ8^~ZNU-~v  
-f|+  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ^RF mRn  
*`pec3"  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ}HA2c e\  
aP6%OI  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) Vp{RX8?.  
|+4E 8;4_  
ÃâÒßѧרҵ£º [}xIg8  
<g|nmu)o$  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ BB73' W8y  
wHN` - 5 %  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? M'!!EQo  
U}vtVvx  
´«È¾²¡Ñ§×¨Òµ£º I;":O"ij\  
1r-,V X7  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ :R|2z`b!  
*i]Z=  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£  k9VQ6A  
YWBP'Mo  
Ïû»¯×¨Òµ£º 2QuypVC ]  
s)7`r6w  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ 7zk m  
$lG--s  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? >8mW-p  
J`D<  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ va*>q-QCr  
Hd@T8 D*A  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© $MVeMgPa  
BxN#Nk~  
1. Fas(CD95)/FasL ?Kz` O>"6  
FVLA^$5 c  
2. common chain of cytokine receptor P9HPr2  
P*^UU\x'4I  
3 . TCR/CD3 complex %$-3fj7  
f*H}eu3/j  
4. negaive selection of thymocytes [(^''*7r+T  
WAXrA$:3J  
5. artificial active immune ).#D:eO[~  
cngPc]?N  
6. anti-idiotypic 7^}Z %c  
Tf]VcEF  
7. IgSF sBG(CpQ  
ZFw743G  
8. Integrin f2K3*}P  
'`VO@a  
9. chemokine /]58:euR  
{y%O_-C'r  
10. B7/CD28 *m Tc4&*  
UVRV7^eTe  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© IaqN@IlWb  
.:Xe*Q  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ t-{OP?cE1  
Z19y5?uR  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ -BH'.9uqGQ  
Wl"fh_  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ ;Awzm )Q  
dKG<"  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ a'.=.eDQ  
SQCuY<mD  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ N^j''siB  
)CU(~s|s  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ l1j   
6/C  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© $ O>MV  
gKEvgXOj  
1. B7/CD28 ?["ZEa  
KW kT 9[H  
2. Th1 subset <AXYqH7%A  
Lg53 Ms%  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© 7E]l=Z`x  
*gKr1}M  
4. antibody affinity maturation }jXUd=.Nu  
Z ISd0hV  
5. AP-1 %iML??S  
&wvv5Vd  
6. single chain variable fragment£¨ScFv£© w/@%xy  
tt91)^GdYa  
7. NK cell receptor vDL/PXNC  
m]vr|:{6/  
8. Zinkernagel-Doherty phenomenon my0->W%L  
n*uZ=M_/Q  
9. Ig fold C <)&qx3  
pu#<qD*w  
10. CD40/CD40L {,X( fJ  
%stktVDAP  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© 2y,wN"qH*  
4 ]R3*F  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ bL%)k61G_v  
`VbG%y&I  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿  q\"$~*  
HB^azHr  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ ];YOP%2   
CaMG$X&O  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ pcG q  
X35hLp8 M  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 5 Da( DA  
04TV. /uA  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ (@9-"W  
#c_ZU\" h"  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ .#}R$}e+  
:gn!3P}p?  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ^EZoP:x(oE  
jw)t"S/E  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Qpc>5p![3  
MtljI6  
1.Co-stimulators (or co-stimulating molecules) `7`iCYiTy  
.'M]cN~  
2.NK-kB KAGq\7  
9,IGZ55C  
3.Immunoglobulin superfamily OB:G5B`  
IN"qJ3<k  
4.antigen-presenting cell (APC) (Y86q\DQ?|  
<v?-$3YT  
5.death domain rQF%;  
q :gH`5N  
6.CCR and CXCR !#QD;,SE+  
G7u7x?E:B`  
7.Lectin (or mitogen) ouuj d~b+  
aE+E'iL  
8.Clusters of differentiation, CD) hM-qC|!  
z 'j%.Dd8  
9.B7 family V'8 (}(s/  
k~R_Pq S  
10.Cytotoxic T lymphocyte, CTL) 5}f$O  
kC)dia{$  
11.IL-15 and IL-15 receptor (IL-15R) *<KY^;  
8I*fPf  
12.MHC restriction ]>!]X*\9  
mR@iGl\\  
13.Affinity-chromatography NWFZ:h@v  
>[[< 5$,T  
14.Cyctosprin A, CsA wI)W:mUZZ  
= fm/l-P@  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) Da.vyp  
tP`,Egf"g  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© UJO+7h'  
k(et b#  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 nfd^'}$]  
h.PY$W<  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ _T H'v:C  
{jbOcx$t  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ k9a-\UIMet  
(xMAo;s_  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Bp9 u6R  
bj bm"~  
ÃâÒßѧרҵ£º 5'6Oan7dL:  
2: fSn&*/>  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ znD0&CS9q  
21W>}I"0?  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 0&zp9(G5  
ho 4~-xmN  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ ^dRB(E}|)  
kz]qk15w  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) %vgn>A?]1  
aR+vY1d"  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) p%8y!^g  
*IfLoKS'  
1. ADCC(antibody dependent cell-mediated cytotoxicity) <\Lii0hi!  
|}=xA%)  
2. »·æß¾úËØ(cyclosporin) .*i.Z   
/a Nlr>^  
3. KIR(killer cell inhibitory receptor) fn;`Vit#  
_I+QInD;)  
4. HLDA(human leucocyte differentiation antigen) AfB,`l`k  
AKu]c-  
5. Interleukin 18(IL-18) =wtu  
Gg$4O8  
6. ÕûºÏËØ(integrin) D.su^m_1  
 ]?M3X_Mq  
7. Fas/FasL \AQ*T`Dq  
5LMAy"  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) jI[Y< (F ;  
E9<oA.  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) {Dupk0'(  
eaB6e@]@  
10. Th1/Th2 n%X5TJE  
';'gKX!9V  
11. »ùÒòÒßÃç(DNAÒßÃç) )jm!bR`  
-Ph"#R&  
12. chemokines and chemokine receptor YMXhzqj  
B:oE&Ahh{  
13. ÃâÒßÄÍÊÜ %1h%#/ #[  
t.X8 c/,;g  
14. ¹²´Ì¼¤·Ö×Ó Op<,e{[]  
e>J.r("f  
15. ËÀÍö½á¹¹Óò(death domain) Z@(m.&ZRx  
7fE U5@  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) GBSuTu8  
yVfF *nG  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? }-/oL+j  
H'a6] ]2  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠY+)qb);  
L NS O]\  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î  hik.c3  
!(A<  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ JO-FnoQK  
%1\~OnT  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå tZ>'tE   
s.$:.* k  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ <I 0EjV  
O%s7}bR3  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 'r'+$D7  
 | \FJ  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ @Ta0v:Y  
\ lW*.<  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ `D $ "K1u  
QC Jf   
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»